Jessica A. Bisignano

Jessica A. Bisignano

Partner Corporate & Finance

Philadelphia

+1 267 675 4643

[email protected]

Jessica A. Bisignano

Overview
Experience
Credentials
Insights and events

Jessica A. Bisignano advises both public and private companies in a variety of transactions and on day-to-day corporate legal matters. She works closely with clients to get to know their businesses, understand their strategic goals, and help them anticipate and resolve issues that arise during the course of a transaction or representation.

Jessica focuses on domestic and cross-border business transactions, representing public and private companies in a range of strategic transactions, including mergers and acquisitions, divestitures, and joint ventures. She also advises clients on strategic investments and on SEC disclosure, and corporate governance matters. Jessica has represented companies spanning a number of industries, particularly in the life sciences, pharmaceutical, consumer, and financial services sectors.

Representative experience

Represented a leading developer and manufacturer of recombinant proteins in its auction and subsequent US$1.85bn sale to a global supplier of scientific instrumentation, reagents, and consumables.

Represents a developer of a 3D geolocation services in public company aspects of its SPAC merger and ongoing SEC reporting and Nasdaq compliance.

Represented a life sciences and health care contract manufacturing company in its auction and subsequent sale to a leading manufacturer of consumer goods.

Represented a clinical-stage biopharmaceutical company focused on respiratory diseases in its acquisition of a private drug development company focused on therapeutics for rare pulmonary diseases.

Represented a global leader of life science research and clinical diagnostic products in multiple acquisitions and investment transactions coupled with options to acquire.

Represented a multinational specialty pharmaceutical company in an option to acquire ophthalmology assets of a private ophthalmology company.

Represented a late-stage clinical company, on its reverse merger with a private clinical-stage cell therapy company, resulting in a combined company value of approximately USD$366m.

Represented a global biopharmaceutical company on its investment in and option to acquire a biotech start-up and its separate acquisition of certain assets from an early-stage pharmaceutical company.

Represents a domestic beauty retailer in strategic investments and a separate acquisition of certain assets from a technology start-up.